Compare VVR & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VVR | MRVI |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 509.5M | 472.8M |
| IPO Year | N/A | 2020 |
| Metric | VVR | MRVI |
|---|---|---|
| Price | $3.32 | $3.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $4.57 |
| AVG Volume (30 Days) | 692.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 11.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $192,435,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.55 | $1.67 |
| 52 Week High | $4.38 | $4.40 |
| Indicator | VVR | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 32.07 |
| Support Level | $3.29 | $3.06 |
| Resistance Level | $3.31 | $3.21 |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 90.00 | 0.00 |
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide a high level of current income, consistent with the preservation of capital. The company invests in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.